Background All three nitric oxide synthase (NOS) isoforms are expressed in atherosclerotic plaques. NOS enzymes in general catalyse NO production. However, under conditions of substrate and cofactor deficiency, the enzyme directly catalyse superoxide formation. Considering this alternative chemistry, the effects of NOS on key events in spontaneous hyperlipidemia driven atherosclerosis have not been investigated yet. Here, we evaluate how endothelial nitric oxide synthase (eNOS) modulates leukocyte/endothelial- (L/E) and platelet/endothelial- (P/E) interactions in atherosclerosis and the production of nitric oxide (NO) and superoxide by the enzyme. Principal Findings Intravital microscopy (IVM) of carotid arteries revealed significantly increased L/E-interactions in apolipoproteinE/eNOS double knockout mice (apoE？/？/eNOS？/？), while P/E-interactions did not differ, compared to apoE？/？. eNOS deficiency increased macrophage infiltration in carotid arteries and vascular cell adhesion molecule-1 (VCAM-1) expression, both in endothelial and smooth muscle cells. Despite the expression of other NOS isoforms (inducible NOS, iNOS and neuronal NOS, nNOS) in plaques, Electron Spin Resonance (ESR) measurements of NO showed significant contribution of eNOS to total circulating and vascular wall NO production. Pharmacological inhibition and genetic deletion of eNOS reduced vascular superoxide production, indicating uncoupling of the enzyme in apoE？/？ vessels. Conclusion Overt plaque formation, increased vascular inflammation and L/E- interactions are associated with significant reduction of superoxide production in apoE？/？/eNOS？/？ vessels. Therefore, lack of eNOS does not cause an automatic increase in oxidative stress. Uncoupling of eNOS occurs in apoE？/？ atherosclerosis but does not negate the enzyme's strong protective effects.
References
[1]
Lusis AJ (2000) Atherosclerosis. Nature 407: 233–241.
[2]
Ross R (1993) The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature 362: 801–809.
[3]
Gawaz M, Langer H, May AE (2005) Platelets in inflammation and atherogenesis. J Clin Invest 115: 3378–3384.
[4]
Davignon J, Ganz P (2004) Role of endothelial dysfunction in atherosclerosis. Circulation 109: III27–32.
[5]
Wilcox JN, Subramanian RR, Sundell CL, Tracey WR, Pollock JS, et al. (1997) Expression of multiple isoforms of nitric oxide synthase in normal and atherosclerotic vessels. Arterioscler Thromb Vasc Biol 17: 2479–2488.
[6]
Albrecht EW, Stegeman CA, Heeringa P, Henning RH, van Goor H (2003) Protective role of endothelial nitric oxide synthase. J Pathol 199: 8–17.
[7]
Pou S, Pou WS, Bredt DS, Snyder SH, Rosen GM (1992) Generation of superoxide by purified brain nitric oxide synthase. J Biol Chem 267: 24173–24176.
[8]
Xia Y, Roman LJ, Masters BS, Zweier JL (1998) Inducible nitric-oxide synthase generates superoxide from the reductase domain. J Biol Chem 273: 22635–22639.
[9]
Xia Y, Tsai AL, Berka V, Zweier JL (1998) Superoxide generation from endothelial nitric-oxide synthase. A Ca2+/calmodulin-dependent and tetrahydrobiopterin regulatory process. J Biol Chem 273: 25804–25808.
[10]
Kuhlencordt PJ, Gyurko R, Han F, Scherrer-Crosbie M, Aretz TH, et al. (2001) Accelerated atherosclerosis, aortic aneurysm formation, and ischemic heart disease in apolipoprotein E/endothelial nitric oxide synthase double-knockout mice. Circulation 104: 448–454.
[11]
Kuhlencordt PJ, Hotten S, Schodel J, Rutzel S, Hu K, et al. (2006) Atheroprotective effects of neuronal nitric oxide synthase in apolipoprotein e knockout mice. Arterioscler Thromb Vasc Biol 26: 1539–1544.
[12]
Kuhlencordt PJ, Chen J, Han F, Astern J, Huang PL (2001) Genetic deficiency of inducible nitric oxide synthase reduces atherosclerosis and lowers plasma lipid peroxides in apolipoprotein E-knockout mice. Circulation 103: 3099–3104.
[13]
Detmers PA, Hernandez M, Mudgett J, Hassing H, Burton C, et al. (2000) Deficiency in inducible nitric oxide synthase results in reduced atherosclerosis in apolipoprotein E-deficient mice. J Immunol 165: 3430–3435.
[14]
Kubes P, Suzuki M, Granger DN (1991) Nitric oxide: an endogenous modulator of leukocyte adhesion. Proc Natl Acad Sci U S A 88: 4651–4655.
[15]
Sanz MJ, Hickey MJ, Johnston B, McCafferty DM, Raharjo E, et al. (2001) Neuronal nitric oxide synthase (NOS) regulates leukocyte-endothelial cell interactions in endothelial NOS deficient mice. Br J Pharmacol 134: 305–312.
[16]
Lefer DJ, Jones SP, Girod WG, Baines A, Grisham MB, et al. (1999) Leukocyte-endothelial cell interactions in nitric oxide synthase-deficient mice. Am J Physiol 276: H1943–1950.
[17]
Gauthier TW, Davenpeck KL, Lefer AM (1994) Nitric oxide attenuates leukocyte-endothelial interaction via P-selectin in splanchnic ischemia-reperfusion. Am J Physiol 267: G562–568.
[18]
De Caterina R, Libby P, Peng HB, Thannickal VJ, Rajavashisth TB, et al. (1995) Nitric oxide decreases cytokine-induced endothelial activation. Nitric oxide selectively reduces endothelial expression of adhesion molecules and proinflammatory cytokines. J Clin Invest 96: 60–68.
[19]
Massberg S, Brand K, Gruner S, Page S, Muller E, et al. (2002) A critical role of platelet adhesion in the initiation of atherosclerotic lesion formation. J Exp Med 196: 887–896.
[20]
Michelson AD, Benoit SE, Furman MI, Breckwoldt WL, Rohrer MJ, et al. (1996) Effects of nitric oxide/EDRF on platelet surface glycoproteins. Am J Physiol 270: H1640–1648.
[21]
Stamler J, Mendelsohn ME, Amarante P, Smick D, Andon N, et al. (1989) N-acetylcysteine potentiates platelet inhibition by endothelium-derived relaxing factor. Circ Res 65: 789–795.
[22]
Cerwinka WH, Cooper D, Krieglstein CF, Feelisch M, Granger DN (2002) Nitric oxide modulates endotoxin-induced platelet-endothelial cell adhesion in intestinal venules. Am J Physiol Heart Circ Physiol 282: H1111–1117.
[23]
Theilmeier G, Michiels C, Spaepen E, Vreys I, Collen D, et al. (2002) Endothelial von Willebrand factor recruits platelets to atherosclerosis-prone sites in response to hypercholesterolemia. Blood 99: 4486–4493.
[24]
Huie RE, Padmaja S (1993) The reaction of no with superoxide. Free Radic Res Commun 18: 195–199.
[25]
White CR, Brock TA, Chang LY, Crapo J, Briscoe P, et al. (1994) Superoxide and peroxynitrite in atherosclerosis. Proc Natl Acad Sci U S A 91: 1044–1048.
[26]
Landmesser U, Dikalov S, Price SR, McCann L, Fukai T, et al. (2003) Oxidation of tetrahydrobiopterin leads to uncoupling of endothelial cell nitric oxide synthase in hypertension. J Clin Invest 111: 1201–1209.
[27]
Vasquez-Vivar J, Kalyanaraman B, Martasek P, Hogg N, Masters BS, et al. (1998) Superoxide generation by endothelial nitric oxide synthase: the influence of cofactors. Proc Natl Acad Sci U S A 95: 9220–9225.
Massberg S, Eisenmenger S, Enders G, Krombach F, Messmer K (1998) Quantitative analysis of small intestinal microcirculation in the mouse. Res Exp Med (Berl) 198: 23–35.
[30]
Kleschyov AL, Mollnau H, Oelze M, Meinertz T, Huang Y, et al. (2000) Spin trapping of vascular nitric oxide using colloid Fe(II)-diethyldithiocarbamate. Biochem Biophys Res Commun 275: 672–677.
[31]
Hall DM, Buettner GR (1996) In vivo spin trapping of nitric oxide by heme: electron paramagnetic resonance detection ex vivo. Methods Enzymol 268: 188–192.
[32]
Dikalov S, Fink B (2005) ESR techniques for the detection of nitric oxide in vivo and in tissues. Methods Enzymol 396: 597–610.
[33]
Fink B, Laude K, McCann L, Doughan A, Harrison DG, et al. (2004) Detection of intracellular superoxide formation in endothelial cells and intact tissues using dihydroethidium and an HPLC-based assay. Am J Physiol Cell Physiol 287: C895–902.
[34]
Dikalova A, Clempus R, Lassegue B, Cheng G, McCoy J, et al. (2005) Nox1 overexpression potentiates angiotensin II-induced hypertension and vascular smooth muscle hypertrophy in transgenic mice. Circulation 112: 2668–2676.
[35]
Schafer A, Fraccarollo D, Pfortsch S, Flierl U, Vogt C, et al. (2008) Improvement of vascular function by acute and chronic treatment with the PDE-5 inhibitor sildenafil in experimental diabetes mellitus. Br J Pharmacol 153: 886–893.
[36]
Chen J, Kuhlencordt PJ, Astern J, Gyurko R, Huang PL (2001) Hypertension does not account for the accelerated atherosclerosis and development of aneurysms in male apolipoprotein e/endothelial nitric oxide synthase double knockout mice. Circulation 104: 2391–2394.
[37]
Bevilacqua MP, Pober JS, Mendrick DL, Cotran RS, Gimbrone MA Jr (1987) Identification of an inducible endothelial-leukocyte adhesion molecule. Proc Natl Acad Sci U S A 84: 9238–9242.
[38]
Kuhlencordt PJ, Rosel E, Gerszten RE, Morales-Ruiz M, Dombkowski D, et al. (2004) Role of endothelial nitric oxide synthase in endothelial activation: insights from eNOS knockout endothelial cells. Am J Physiol Cell Physiol 286: C1195–1202.
[39]
Massberg S, Schurzinger K, Lorenz M, Konrad I, Schulz C, et al. (2005) Platelet adhesion via glycoprotein IIb integrin is critical for atheroprogression and focal cerebral ischemia: an in vivo study in mice lacking glycoprotein IIb. Circulation 112: 1180–1188.
[40]
Huo Y, Schober A, Forlow SB, Smith DF, Hyman MC, et al. (2003) Circulating activated platelets exacerbate atherosclerosis in mice deficient in apolipoprotein E. Nat Med 9: 61–67.
[41]
Knowles JW, Reddick RL, Jennette JC, Shesely EG, Smithies O, et al. (2000) Enhanced atherosclerosis and kidney dysfunction in eNOS(？/？)Apoe(？/？) mice are ameliorated by enalapril treatment. J Clin Invest 105: 451–458.
[42]
Ponnuswamy P, Ostermeier E, Schrottle A, Chen J, Huang PL, et al. (2009) Oxidative stress and compartment of gene expression determine proatherosclerotic effects of inducible nitric oxide synthase. Am J Pathol 174: 2400–2410.
[43]
Ozaki M, Kawashima S, Yamashita T, Hirase T, Namiki M, et al. (2002) Overexpression of endothelial nitric oxide synthase accelerates atherosclerotic lesion formation in apoE-deficient mice. J Clin Invest 110: 331–340.
[44]
Ohara Y, Peterson TE, Harrison DG (1993) Hypercholesterolemia increases endothelial superoxide anion production. J Clin Invest 91: 2546–2551.
[45]
Sorescu D, Weiss D, Lassegue B, Clempus RE, Szocs K, et al. (2002) Superoxide production and expression of nox family proteins in human atherosclerosis. Circulation 105: 1429–1435.
